End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
135 SAR | -1.75% | -1.03% | +20.75% |
03-28 | Mouwasat Medical Services Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-25 | Saudi Arabia's Mouwasat Medical Services Reports Improved FY23 Profit, Revenue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.2 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.75% | 7.2B | D | ||
-20.16% | 16.21B | B+ | ||
+4.50% | 12.44B | B | ||
+3.98% | 11.58B | B+ | ||
+9.72% | 10.79B | B+ | ||
-2.19% | 7.68B | A- | ||
+4.49% | 6.67B | B- | ||
+50.89% | 4.66B | - | ||
-5.01% | 4.25B | - | ||
-4.50% | 4.21B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4002 Stock
- Ratings Mouwasat Medical Services Company